Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.
Stephen Schuster, MD, of the Perelman School of Medicine, provides a summary of results seen with CAR T treatments in leukemia, lymphoma, and myeloma.
Transcript
What have been the promising results seen in CAR T treatments for patients with leukemia, lymphoma, and myeloma?
Lots of promising results in leukemia and lymphoma. The myeloma results are early, but the leukemia and lymphoma results have already translated into 2 commercially available products. The leukemia, specifically, is B-cell acute lymphoblastic leukemia (ALL), the leukemia that's most common in children. And the target of therapy is CD19, so this is CARs directed against CD19, which is on the surface of B-call ALL. And there, there's an 80% response rate and at 1 year, 75% of the kids are in good shape, in remission. And these are kids with acute lymphoblastic leukemia, who have disease that is either recurred after standard therapy or doesn't respond to standard therapy, or that have had transplants and have recurrence after transplants. So it offers a potentially long-term, durable remission for these kids.
The lymphoma indication, so far, is diffuse large B-cell lymphoma, and there we have roughly 40% remission rates, regardless of which study you're talking about and which CAR T cell you're talking about, and they're durable. So, I have some of the longest follow-up, which I pulished yesterday in the New England Journal of Medicine, and these patients in remission, it lasts for years. The median follow-up in that report was 29 months, and none of the respondents had relapsed. So, this is a breakthrough for relapsed/refractory lymphoma patients who don't respond to conventional therapies or to salvage therapies.
With regard to myeloma, they're at about where lymphoma was 3 years ago. They need more trials with larger numbers of patients and longer follow-up, bubt preliminarily, the target, BCMA on the malignant plasma cells of myeloma, looks very susceptible to the CAR T approach. Lots of things about CAR T at this meeting; it's clear to me that CAR T cells are a paradigm and we can make CAR T cells to any specific tumor antigens or viral antigens, for that matter, and have a T-cell therapeutic approach.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More